Even after undergoing radical treatment, patients with BCR in PCa may experience clinical progression within a median time of 5 to 8 years, leading to an increased risk of cancer-associated death.[45] Therefore, identifying independent biomarkers for BCR is of great importance for the clinical treatment of PCa. The gene discussed is BCR; the disease is posterior cortical atrophy.